Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Inogen
INGN
Inogen
Pricing Pressures And Rivals Will Erode Portable Oxygen Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
12 Aug 25
Updated
12 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$7.00
10.7% overvalued
intrinsic discount
12 Aug
US$7.75
Loading
1Y
-38.0%
7D
3.9%
Author's Valuation
US$7.0
10.7% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$7.0
10.7% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-96m
498m
2014
2017
2020
2023
2025
2026
2028
Revenue US$498.0m
Earnings US$61.5m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
6.21%
Medical Equipment revenue growth rate
0.44%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.67%
Calculation
US$61.47m
Earnings '28
x
5.70x
PE Ratio '28
=
US$350.29m
Market Cap '28
US$350.29m
Market Cap '28
/
40.06m
No. shares '28
=
US$8.74
Share Price '28
US$8.74
Share Price '28
Discounted to 2025 @ 7.69% p.a.
=
US$7.00
Fair Value '25
